IBKR · NMS · Financial Services
Interactive Brokers Group, Inc.
Also onConsensus Drift
Implied value per share
USD 726.88
Market price
USD 90.69
Implied upside
+701.5%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 13.8bn | USD 18.5bn | USD 24.9bn | USD 33.5bn | USD 45.2bn | +34.6% |
| EBIT | USD 11.3bn | USD 15.2bn | USD 20.5bn | USD 27.6bn | USD 37.1bn | +34.6% |
| NOPAT | USD 10.4bn | USD 14.0bn | USD 18.8bn | USD 25.3bn | USD 34.1bn | +34.6% |
| Add depreciation & amortisation | USD 177.2m | USD 238.5m | USD 321.0m | USD 432.1m | USD 581.5m | +34.6% |
| Less capital expenditure | USD -177.2m | USD -238.5m | USD -321.0m | USD -432.1m | USD -581.5m | +34.6% |
| Less increase in working capital | USD 3.5bn | USD 4.8bn | USD 6.4bn | USD 8.6bn | USD 11.6bn | -34.6% |
| Free cashflow to firm | USD 13.9bn | USD 18.7bn | USD 25.2bn | USD 33.9bn | USD 45.7bn | +34.6% |
| Discount factor | 0.9458 | 0.8461 | 0.7569 | 0.6771 | 0.6058 | - |
| Present value | USD 13.2bn | USD 15.9bn | USD 19.1bn | USD 23.0bn | USD 27.7bn | +20.4% |
| Present Value Of The Forecast | USD 98.8bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 1.234 | Reported 1.349, pulled toward 1.0 (Blume) |
| Cost of equity | 11.78% | Risk-free + beta x equity risk premium |
| Cost of debt | 7.00% | Implied cost of debt of 25569.7% is not a credible funding cost, so risk-free + 2bp is assumed instead. Interest expense and reported debt are measuring different things - common for banks, whose interest expense includes deposits that total debt excludes. |
| Market capitalisation | USD 154.5bn | 100.0% of capital |
| Total debt | USD 19.0m | 0.0% of capital, book value as a proxy |
| Tax rate | 8.1% | Effective, capped at statutory |
| WACC | 11.78% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
69% of EV
- Forecast FCFF, final year
- USD 45.7bn
- Capex at depreciation, working capital in reinvestment
- USD 34.1bn
- Less reinvestment at g/ROIC (4.2% of NOPAT)
- USD -1.4bn
- Capitalised
- USD 32.7bn
- ROIC (reported)
- 60.0%
- Terminal value, undiscounted
- USD 360.6bn
- Terminal value, discounted
- USD 218.5bn
- Enterprise value
- USD 317.2bn
- Less net debt
- USD -4.9bn
- Equity value
- USD 322.2bn
Exit at 16.8x EBITDA
80% of EV
- Terminal value, undiscounted
- USD 634.3bn
- Terminal value, discounted
- USD 384.2bn
- Enterprise value
- USD 483.0bn
- Less net debt
- USD -4.9bn
- Equity value
- USD 488.0bn
Spread between methods: 41%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 9.78% | 849.51 | 885.93 | 927.29 | 974.69 | 1029.57 |
| 10.78% | 756.88 | 784.31 | 815.00 | 849.59 | 888.87 |
| 11.78% | 682.27 | 703.45 | 726.88 | 752.92 | 782.07 |
| 12.78% | 620.89 | 637.59 | 655.87 | 675.98 | 698.22 |
| 13.78% | 569.52 | 582.90 | 597.43 | 613.28 | 630.63 |
Outlined: this model. Green text: above today's price of 90.69. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 34.6% | -15.7% | -50.3pp |
| EBIT margin | 82.1% | 2.9% | -79.3pp |
| Discount rate | 11.8% | 78.6% | +66.9pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.